Replimune

US · REPL #3130 by market cap Listed 2018

13.20 -0.05 -0.38%

Live - 5344 symbols - heartbeat 84s ago · 2026-10-08 07:33

Pre-market 13.28 +0.62%

After-hours 13.20 0.00%

Market cap: 1.24B
P/E (TTM): -4.19
P/B: 11.78
EPS: -3.38
Div yield: 0.00%
52W pos: 79%

Reader sentiment Are you bullish or bearish on REPL?

Anonymous reader poll. Unscientific, not investment advice.

About Replimune

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Founded: 2017
CEO: Dr. Sushil Patel, PhD
Employees: 465
Headquarters: Woburn, Massachusetts, United States of America
Fiscal year end: 03-31
Website: replimune.com

Company profile

Exchange: US
Symbol: REPL
Market-cap rank: #3130
Listing date: 2018-07-20
Market cap: 1.24B
Float cap: 893.02M
Shares out: 94.22M
Float shares: 67.65M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 07:33:55 · For reference only, not investment advice and not tailored to your situation.